Olanzapine-induced Concurrent Tardive Dystonia and Tardive Dyskinesia in Schizophrenia with Intellectual Disability: A Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Tardive dystonia and tardive dyskinesia (TDs) are rare extrapyramidal side effects that develop after long-term use of antipsychotics, but they are different syndromes and rarely occur at the same time. Olanzapine is an atypical antipsychotic drug associated with a low risk of extrapyramidal side effects in schizophrenia, but its associations with tardive movements are not clear. We present a case of a 19-year-old Asian female patient with schizophrenia and intellectual disabilities who developed concurrent TDs after long-term use of olanzapine. At her 10-month follow-up examination, her concurrent TDs had been treated successfully with clozapine. This case demonstrates that although the use of olanzapine to treat psychosis and behavioral disturbances is increasing due to its high efficacy and low rate of extrapyramidal side effects, concurrent TDs should be carefully assessed after long-term use of this antipsychotic, especially in patients with schizophrenia and intellectual disabilities. Clozapine, by preventing or reversing the debilitating consequences of concurrent TDs, may be an effective treatment for these patients.
Abstract
Tardive dystonia and tardive dyskinesia (TDs) are rare extrapyramidal side effects that develop after long-term use of antipsychotics, but they are different syndromes and rarely occur at the same time. Olanzapine is an atypical antipsychotic drug associated with a low risk of extrapyramidal side effects in schizophrenia, but its associations with tardive movements are not clear. We present a case of a 19-year-old Asian female patient with schizophrenia and intellectual disabilities who developed concurrent TDs after long-term use of olanzapine. At her 10-month follow-up examination, her concurrent TDs had been treated successfully with clozapine. This case demonstrates that although the use of olanzapine to treat psychosis and behavioral disturbances is increasing due to its high efficacy and low rate of extrapyramidal side effects, concurrent TDs should be carefully assessed after long-term use of this antipsychotic, especially in patients with schizophrenia and intellectual disabilities. Clozapine, by preventing or reversing the debilitating consequences of concurrent TDs, may be an effective treatment for these patients.
참고문헌 (27)
- 김성환, "Tardive Dystonia Related with Aripiprazole", PSYCHIATRY INVESTIGATION, 14(3), pp.380~382 (2017), 대한신경정신의학회[DOI]
- Friedman JH, "Tardive dystonia in a psychiatric hospital", J Neurol Neurosurg Psychiatry, 50, pp.801~803 (1987)
- Ricciardi L, "Treatment recommendations for tardive dyskinesia", Can J Psychiatry, 64, pp.388~399 (2019)
- van Harten PN, "Tardive dystonia", Schizophr Bull, 25, pp.741~748 (1999)
- Yassa R, "A comparison of severe tardive dystonia and severe tardive dyskinesia", Acta Psychiatr Scand, 80, pp.155~159 (1989)
- Sachdev P, "Risk factors for tardive dystonia : a case-control comparison with tardive dyskinesia", Acta Psychiatr Scand, 88, pp.98~103 (1993)
- Pitzer M, "Tardive movement disorders with antipsychotics – a case of aripirazole-induced tardive dystonia and review of the literature", Z Kinder Jugendpsychiatr Psychother, 45, pp.325~334 (2017)
- Tollefson GD, "Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol", Am J Psychiatry, 154, pp.1248~1254 (1997)
- Lin JJ, "Improvement of generalised dystonia by olanzapine treatment", J Clin Neurosci, 11, pp.84~86 (2004)
- Jaffe ME, "Reduction of tardive dystonia with olanzapine", Am J Psychiatry, 156, pp.2016~ (1999)
- Lucetti C, "Treatment of patients with tardive dystonia with olanzapine", Clin Neuropharmacol, 25, pp.71~74 (2002)
- Truöl S, "Improvement of tardive dyskinesia after treatment with olanzapine", Psychiatr Prax, 29, pp.315~317 (2002)
- Bhanji NH, "Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia", Can J Psychiatry, 49, pp.343~ (2004)
- Szafrański T, "Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions", Psychiatr Pol, 48, pp.1155~1165 (2014)
- Sangroula D, "Clozapine treatment of olanzapine-induced tardive dyskinesia : a case report", J Psychiatr Pract, 23, pp.53~59 (2017)
- Cohen S, "Tardive dyskinesia in the mentally retarded : comparison of prevalence, risk factors and topography with a schizophrenic population", Acta Psychiatr Scand, 83, pp.234~237 (1991)
- Reid AH, "Schizophrenia in mental retardation : clinical features", Res Dev Disabil, 10, pp.241~249 (1989)
- Newell KM, "Onset of dyskinesia and changes in postural task performance during the course of neuroleptic withdrawal", Am J Ment Retard, 107, pp.270~277 (2002)
- van Harten PN, "The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia : the Curaçao Extrapyramidal Syndromes Study II", Schizophr Res, 26, pp.235~242 (1997)
- Kapur S, "5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia : a PET investigation", Am J Psychiatry, 155, pp.921~928 (1998)
- Brown HE, "A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole", Prim Care Companion CNS Disord, 13, pp.PCC.11l011~ (2011)
- Chan CH, "Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia : a 24-week follow-up study", Int Clin Psychopharmacol, 33, pp.155~162 (2018)
- Na-Ri Kang, "Tardive Dyskinesia: Treatment with Aripiprazole", Clinical Psychopharmacology and Neuroscience, 9(1), pp.1~8 (2011), 대한정신약물학회
- Lim HK, "Tardive dystonic symptoms associated with aripiprazole treatment", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.589~590 (2008)
- Trugman JM, "Treatment of severe axial tardive dystonia with clozapine:case report and hypothesis", Mov Disord, 9, pp.441~446
- Simpson GM, "The treatment of tardive dyskinesia and tardive dystonia", J Clin Psychiatry, 61(Suppl 4), pp.39~44 (2000)
- Lako IM, "Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics : a meta-analysis", J Clin Psychopharmacol, 33, pp.675~681 (2013)